Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Rust

Internal Medicine Monaca, PA Medical Doctor

NPI 1982914651 CMS profile 271460

79 Wagner Rd, Monaca, PA 15061

Open in the dashboard

General payments

$115,214

1,573 records reported · program years 2019–2025

Research payments

$1,569

Paid to them · 21 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$84,513 paid to institutions, not to them · program years 2019–2023

Through program year 2025, William Rust of Monaca, PA is reported in the CMS Open Payments database as having received $115,214 across 1,573 general payments and $1,569 in research payments paid to them. Separately, studies naming them as principal investigator received $84,513 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $23,186 219
2024 General $28,255 210
2023 General $31,020 242
2022 General $19,009 219
2021 General $5,164 245
2020 General $3,958 207
2019 General $4,623 231
2019 Research $1,569 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Rust
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to William Rust were reported at $23,186. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year William Rust Internal Medicine median Middle half National median
2019 $4,623 $159 $48–$570 $163
2020 $3,958 $119 $33–$402 $114
2021 $5,164 $135 $37–$521 $132
2022 $19,009 $141 $42–$496 $149
2023 $31,020 $149 $45–$519 $160
2024 $28,255 $154 $47–$537 $164
2025 $23,186 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $50,008 216 payments
  2. Amgen Inc. $40,739 165 payments
  3. GlaxoSmithKline, LLC. $3,806 154 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $2,762 135 payments
  5. Janssen Pharmaceuticals, Inc $2,569 103 payments
  6. Pfizer Inc. $2,004 156 payments
  7. AbbVie, Inc. $1,812 102 payments
  8. Lilly USA, LLC $1,502 87 payments
  9. AstraZeneca Pharmaceuticals LP $1,174 49 payments
  10. Astellas Pharma US Inc $1,170 44 payments
  11. Other $7,667 362 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $79,961 60 payments
  2. Food and Beverage $30,135 1,476 payments
  3. Travel and Lodging $3,765 19 payments
  4. Consulting Fee $993 3 payments
  5. Education $359 15 payments
Products named General payments · program years 2019–2025
  1. Repatha Cardiology $33,250 111 payments
  2. Ozempic $24,879 114 payments
  3. RYBELSUS $21,517 89 payments
  4. REPATHA Cardiovascular $6,908 21 payments
  5. TRELEGY ELLIPTA $2,793 111 payments
  6. JARDIANCE $1,939 78 payments
  7. XARELTO $1,895 84 payments
  8. ELIQUIS $1,433 113 payments
  9. Otezla $1,031 65 payments
  10. DUPIXENT $993 3 payments
  11. Other $23,905 1,404 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Gilead Sciences, Inc. $855 13 payments
  2. AbbVie, Inc. $714 8 payments

Prescribing to Medicare patients

Part D · data year 2024 · 194 drugs

Part D claims

16,378

Median for Internal Medicine: 777

Drug cost

$2,031,708

Median for Internal Medicine: $73,373

Branded share of claims

22.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 279 $359,853
Jardiance Empagliflozin Brand 235 $286,430
Eliquis Apixaban Brand 187 $187,575
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 192 $182,316
Xarelto Rivaroxaban Brand 117 $106,947
Trulicity Dulaglutide Brand 49 $61,605
Repatha Sureclick Evolocumab Brand 73 $59,608
Farxiga Dapagliflozin Propanediol Brand 50 $53,658
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 82 $48,694
Entresto Sacubitril/Valsartan Brand 33 $38,479

The 10 drugs with the highest cost, of 194 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$51,713

Of which drugs: $12,007

Medicare patients

206

Average age 73

Services billed

1,004

97 women, 109 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 43%
Diabetes 24%
Ischemic heart disease 20%
COPD 18%
Atrial fibrillation 15%
Chronic kidney disease 15%
Depression 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 33 33 $2,700

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 43 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
$13,141 87 —
RYBELSUS
$6,065 — —
Ozempic
$4,861 279 —
DUPIXENT
$993 — —
MOUNJARO
$268 19 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 43 with Patron

Records

1,594 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record